Prevnar 13Treatment for Pneumococcal Disease Prophylaxis
Update: Prevnar 13 Now FDA Approved - February 24, 2010
BLA Submitted for Prevnar 13
Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
COLLEGEVILLE, Pa., March 31, 2009 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that it has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Prevnar 13, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein). Last year, the FDA granted Prevnar 13 Fast Track designation, which is designed to facilitate review of products that address serious or potentially life-threatening conditions for which there is an unmet medical need.
Prevnar 13 is designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death worldwide. Seven of these serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) are included in Prevnar(R), Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM(197) Protein) - the current global standard in PD prevention in infants and young children. The six additional serotypes (1, 3, 5, 6A, 7F and 19A) are associated with the greatest remaining burden of invasive disease. Both Prevnar 13 and Prevnar use CRM(197) - an immunological carrier protein with a 20-year history of use in pediatric vaccines.
"We are pleased that, with this milestone, we are now one step closer to bringing Prevnar 13 to infants and children," says Emilio Emini, Ph.D., Executive Vice President, Vaccine Research and Development, Wyeth Pharmaceuticals. "Prevnar, our currently available vaccine, has both proven clinical efficacy and documented effectiveness, which has resulted in a significant public health impact. Prevnar 13 builds on the scientific foundation of Prevnar and, if approved, will provide coverage for the 13 most prevalent pneumococcal serotypes associated with pneumococcal disease, including serotype 19A, which has emerged as a serious public health threat in the United States and around the world."
The Prevnar 13 submission to the FDA includes data from 13 Phase 3 studies, involving more than 7,000 infants and young children. The Company initiated its global pediatric filings in late 2008 and, to date, has submitted regulatory applications for the 13-valent candidate vaccine in more than 40 countries worldwide. Prevnar 13 is also being studied in global Phase 3 clinical trials in adults, with regulatory submissions expected in 2010.
Pneumococcal disease is complex and describes a group of illnesses, all of which are caused by the bacterium . PD affects both children and adults and includes invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media (middle ear infection).
Following the inclusion of Prevnar into the routine pediatric immunization schedule in the United States, there has been a 98 percent (95% CI: 97%-99%) reduction in vaccine-type IPD and a 77 percent reduction in all IPD among children younger than 5 years of age through 2005, compared with a pre-licensure baseline. In addition, the incidence of disease caused by the seven conjugate vaccine serotypes declined 55 percent (95% CI: 51%-58%) among adults 50 years of age or older, an unvaccinated group. The Centers for Disease Control and Prevention has reported an increase in the incidence of IPD due to non-vaccine serotypes in children younger than 5 years of age and in adults 40 years of age and older; it is unknown whether these effects would be observed in other populations.
Most recently, serotype 19A, which is included in the candidate vaccine, has been increasing in prevalence in many regions of the world and is frequently resistant to antibiotics. In fact, serotype 19A has emerged as the predominant invasive pneumococcal serotype in the United States.
Prevnar, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM(197) Protein) is indicated for active immunization of infants and toddlers against serious invasive disease caused by , including bacteremia (bloodstream infection) and meningitis (infection of the membranes surrounding the brain and spinal cord) caused by the seven serotypes in the vaccine. The seven serotypes (strains) of included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) are the strains that most commonly caused these serious diseases in children prior to the introduction of Prevnar. The routine vaccination schedule is 2, 4, 6, and 12 to 15 months of age.
Prevnar is also indicated for immunization of infants and toddlers against otitis media (ear infections) caused by the seven serotypes included in the vaccine. Protection against ear infections is expected to be less than that for invasive disease.
As with any vaccine, Prevnar may not protect all individuals receiving the vaccine from serious invasive disease cause by . This vaccine should not be used for treatment of active infection.
In clinical trials, the most frequently reported adverse events included injection site reactions, fever (greater than or equal to 38 degrees Celsius /100.4 degrees Fahrenheit), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash.
Risks are associated with all vaccines, including Prevnar. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. Prevnar does not protect 100% of children vaccinated. Immunization with Prevnar does not substitute routine diphtheria immunization.
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
CONTACT: Lili Gordon of Wyeth Pharmaceuticals, +1-484-865-6671; or DouglasPetkus, +1-973-660-5218, or Investor: Justin Victoria, +1-973-660-5340,both of Wyeth
Ticker Symbol: (NYSE:WYE)
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: March 2009
- Pfizer Receives FDA Approval for Prevnar 13 in Adults Age 18 Through 49 - July 12, 2016
- Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And Adolescents Aged 6 Years Through 17 Years For The Prevention Of Invasive Pneumococcal Disease - January 25, 2013
- FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older - January 3, 2012
- FDA Approves Prevnar 13 Pneumococcal Disease Vaccine - February 24, 2010
- Pfizer Provides U.S. Regulatory Update On Prevnar 13 Vaccine - January 5, 2010
- Wyeth Provides Regulatory Update on Prevnar 13 in the United States - August 12, 2009